GvHD Hub (@gvhd_hub) 's Twitter Profile
GvHD Hub

@gvhd_hub

A global online platform providing latest treatment options and medical information in graft-versus-host disease (GvHD). #gvhd
linktr.ee/GraftVersusHost

ID: 926010699993763841

linkhttp://www.gvhdhub.com/ calendar_today02-11-2017 08:58:50

2,2K Tweet

4,4K Followers

987 Following

GvHD Hub (@gvhd_hub) 's Twitter Profile Photo
GvHD Hub
@gvhd_hub

2 months ago

New publication 📝 3-year final analysis of the REACH3 trial, published in Journal of Clinical Oncology, shows ruxolitinib achieved longer median FFS (38.4 months vs 5.7 months) and DoR (not reached vs 6.4 months) vs best available therapy in patients with SR/D-cGvHD. Learn more:

New publication 📝 3-year final analysis of the REACH3 trial, published in <a href="/JCO_ASCO/">Journal of Clinical Oncology</a>, shows ruxolitinib achieved longer median FFS (38.4 months vs 5.7 months) and DoR (not reached vs 6.4 months) vs best available therapy in patients with SR/D-cGvHD. Learn more: